Psyllium in Pediatric IBS (Psyllium)

May 21, 2026 updated by: Dr Bruno Chumpitazi, M.D.

Assessing Psyllium Given With Meals for Fructan Sensitivity in Children With Irritable Bowel Syndrome

The goal of this clinical trial is to learn if a fiber (psyllium) can change the way bacteria use fructans (a type of sugar) and whether psyllium can help decrease childhood irritable bowel syndrome (IBS) symptoms when eating fructans. The main questions it aims to answer are:

Aim 1: The effect of psyllium at two doses given with a fructan meal on microbial fructan fermentation (intracolonic pH; H2 gas production; gut microbiome composition; fecal short-chain fatty acids, lactate, glycomics).

Aim 2: Determine the impact of psyllium given with a fructan meal on fructan-induced GI symptoms.

Participants will first be asked to eat a specific diet over two three-day periods to determine if fructans worsen their IBS symptoms. Those with worsening symptoms with fructans will be asked to participate in the second part of the study. This includes two weeks of baseline (no change in diet) and two weeks of eating a specific diet with fructans with either psyllium or glucose. Participants will be asked to complete pain and stool diaries, submit stool specimens, swallow a pill to capture gut acid levels, and give breath samples.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

110

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • North Carolina
      • Durham, North Carolina, United States, 27705
        • Recruiting
        • Duke University
        • Contact:
        • Principal Investigator:
          • Bruno Chumpitazi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Children between the ages of 12-17 years meeting pediatric Rome IV criteria for IBS

Exclusion Criteria:

  • Children who have had previous bowel surgery, have documented GI disorders (e.g., ulcerative colitis), or a serious chronic medical condition (e.g., diabetes)
  • weight and/or height are > or < 2 SD for age
  • have chronic conditions with GI symptoms (e.g., cystic fibrosis)
  • have been on antibiotics or probiotics within 3 months (because of potential alterations to the GI microbiome0
  • girls who are pregnant (tested with urine beta-human chorionic gonadotropin at the initial visit)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Psyllium (0.7 g/year of age per day) given with fructans
Participants will receive Psyllium (0.7 g/year of age per day) given with fructans (daily dose 0.5 g/kg up to 19 grams)
Psyllium (0.7 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
Active Comparator: Psyllium (0.5 g/year of age per day) given with fructans
Participants will receive Psyllium (0.5 g/year of age per day) given with fructans (daily dose 0.5 g/kg up to 19 grams)
Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
Psyllium (0.5 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
Placebo Comparator: Placebo (0.7 g/year of age glucose) given with fructans
Participants will receive Placebo (0.7 g/year of age glucose) given with fructans (daily dose 0.5 g/kg up to 19 grams).
Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
Placebo (0.7 g/year of age glucose) (Staleydex 333; Tate & Lyle, Staley, London, UK)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in microbiome composition measured via taxonomic profiling using 16S ribosomal RNA gene amplicon sequencing
Time Frame: Baseline, 2 weeks
Baseline, 2 weeks
Change in fecal lactate
Time Frame: Baseline, 2 weeks
Baseline, 2 weeks
Change in fecal short-chain fatty acids
Time Frame: Baseline, 2 weeks
Baseline, 2 weeks
Change in hydrogen gas production
Time Frame: Baseline, 2 weeks
Baseline, 2 weeks
Change in fecal fructans
Time Frame: Baseline, 2 weeks
Baseline, 2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in abdominal pain frequency
Time Frame: Baseline, 2 weeks
Baseline, 2 weeks
Change in abdominal pain severity
Time Frame: Baseline, 2 weeks
Participants will rate abdominal pain on a scale of 0-10, with higher scores indicating more severe pain.
Baseline, 2 weeks
Change in bloating severity
Time Frame: Baseline, 2 weeks
Participants will rate bloating on a scale of 0-10, with higher scores indicating worse bloating.
Baseline, 2 weeks
Change in flatulence severity
Time Frame: Baseline, 2 weeks
Participants will rate flatulence on a scale of 0-10, with higher scores indicating worse flatulence.
Baseline, 2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Bruno Chumpitazi, MD, MPH, Duke University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2025

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

September 30, 2027

Study Registration Dates

First Submitted

September 25, 2024

First Submitted That Met QC Criteria

October 10, 2024

First Posted (Actual)

October 15, 2024

Study Record Updates

Last Update Posted (Actual)

May 26, 2026

Last Update Submitted That Met QC Criteria

May 21, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe